FCHS Aims for $12M IPO, Reverse Split, CEO Cedes Super-Voting Control

TL;DR

**FCHS is making a high-risk play for capital with a complex preferred stock offering and a massive reverse split, but the CEO giving up super-voting rights is a bullish governance move.**

AI Summary

First Choice Healthcare Solutions, Inc. (FCHS) is filing an S-1/A to register 2,400,000 shares of Series D Convertible Preferred Stock and accompanying Warrants, aiming to raise $12,000,000 in gross proceeds at a public offering price of $5.00 per share and warrant. After underwriting discounts of $0.40 per share, or $960,000, the company expects to receive $11,040,000 before other expenses. The offering also includes up to 8,124,000 shares of common stock underlying the preferred stock and warrants, including those for dividend payments and potential conversion price adjustments. Concurrently, selling stockholders may offer up to 720,000 shares of common stock, including 51,114 shares from warrant exercises, at a fixed price of $5.00 per share until national exchange listing. A 1-for-2,000 reverse stock split, approved on September 15, 2024, will be effected prior to listing, reducing outstanding common shares from 32,958,288. Post-offering, the CEO, Lance Friedman, will cancel all 4 shares of Series A Super Voting Preferred Stock, eliminating his super-voting control.

Why It Matters

This S-1/A filing signals First Choice Healthcare Solutions' intent to raise significant capital, potentially improving its financial stability and growth prospects. The $12 million offering, coupled with a 1-for-2,000 reverse stock split, aims to make the stock more attractive for institutional investors and potentially facilitate a national exchange listing. The cancellation of CEO Lance Friedman's Series A Super Voting Preferred Stock is a critical governance shift, moving the company away from 'controlled company' status and potentially increasing investor confidence by democratizing voting power. However, the complex structure of convertible preferred stock and warrants, along with anti-dilution provisions, introduces significant dilution risk for existing common shareholders, especially given the lack of a floor price on the conversion price.

Risk Assessment

Risk Level: high — The offering involves a high degree of risk due to the complex Series D Convertible Preferred Stock and Warrants, which lack an established trading market and have limited liquidity. The anti-dilution provisions, which require lowering the conversion price if future securities are issued below $5 per share, create significant potential for dilution for common shareholders, with no floor price on the conversion price. Furthermore, the company explicitly states it may not have sufficient authorized shares to satisfy conversions if the conversion price drops significantly, requiring a time-consuming and expensive increase in authorized shares.

Analyst Insight

Investors should exercise extreme caution and thoroughly understand the complex dilution mechanics of the Series D Convertible Preferred Stock and Warrants before considering an investment. Given the high dilution risk and lack of an established market for the preferred stock, a wait-and-see approach is advisable until the company demonstrates stable financial performance and a clear path to profitability post-offering. Monitor the actual conversion price adjustments and the company's ability to manage its capital structure.

Executive Compensation

Key Numbers

• $12,000,000 — Total Public Offering Price (Gross proceeds from the offering of Series D Convertible Preferred Stock and Warrants)
• $5.00 — Public Offering Price per Share/Warrant (Combined price for one share of Offered Preferred Stock and one Warrant)
• $11,040,000 — Proceeds to Company (before expenses) (Net proceeds after $960,000 in underwriting discounts)
• 2,400,000 — Shares of Series D Convertible Preferred Stock (Number of shares offered in the IPO)
• 2,400,000 — Warrants to Purchase Series D Convertible Preferred Stock (Number of warrants offered in the IPO)
• 8,124,000 — Total Common Stock Registered (Estimated shares issuable upon conversion of preferred stock, warrants, and dividends)
• 720,000 — Shares for Resale by Selling Stockholders (Number of common shares potentially sold by existing shareholders)
• 1 for 2,000 — Reverse Stock Split Ratio (Approved reverse split for common stock outstanding as of December 8, 2025)
• 4 — Series A Super Voting Preferred Stock Shares (Number of super-voting shares held by CEO Lance Friedman to be cancelled)
• 5 — Warrant Expiration Anniversary (Warrants will expire on the fifth anniversary of the initial issuance date)

Key Players & Entities

• First Choice Healthcare Solutions, Inc. (company) — Registrant in S-1/A filing
• Lance Friedman (person) — Chief Executive Officer of First Choice Healthcare Solutions, Inc.
• RBW Capital Partners LLC (company) — Representative of the underwriters
• Dawson James Securities, Inc. (company) — Broker-dealer for the offering
• Sichenzia Ross Ference Carmel LLP (company) — Legal counsel for the registrant
• Manatt, Phelps & Phillips LLP (company) — Legal counsel for the registrant
• SEC (regulator) — Securities and Exchange Commission
• NYSE American (company) — Potential listing exchange

FAQ

Risk Factors

• Strategic Pivot Risk [high — operational]: The company is undergoing a significant strategic pivot from its historic orthopedic business to a new model focused on primary care and wellness clinics. This transition involves terminating all remaining legacy orthopedic and Physical Therapy services. There is a risk that the new strategy may not be successful or that the company may not be able to effectively execute the transition, leading to potential financial and operational disruptions.
• Competition in Primary Care and Wellness [high — market]: The primary care and wellness market is highly competitive, with numerous established players and new entrants. The company's success will depend on its ability to differentiate its services, attract and retain patients, and compete effectively on price and quality in key high-growth markets.
• Reliance on Offering Proceeds [high — financial]: The company is seeking to raise $12,000,000 in gross proceeds from this offering. These funds are critical for executing its new strategy. Any failure to complete the offering or to raise the intended amount could significantly impair the company's ability to implement its business plan and achieve its growth objectives.
• Healthcare Regulatory Environment [medium — regulatory]: The healthcare industry is subject to extensive and evolving regulations, including those related to patient privacy (HIPAA), billing and coding, and licensing. Changes in these regulations or non-compliance could result in significant penalties, fines, and reputational damage.
• Potential Dilution from Convertible Securities [medium — legal]: The Series D Convertible Preferred Stock and accompanying Warrants, along with shares underlying potential dividend payments and conversion price adjustments, represent up to 8,124,000 shares of common stock. Conversion of these securities could significantly dilute existing common stockholders.

Industry Context

First Choice Healthcare Solutions is pivoting into the primary care and wellness clinic sector, focusing on anti-aging, weight management, and hormone replacement services. This market is characterized by increasing consumer demand for personalized health solutions and preventative care. However, it is also highly competitive, with established healthcare providers, specialized clinics, and emerging telehealth platforms vying for market share.

Regulatory Implications

The company's new focus on primary care and wellness clinics places it under the purview of extensive healthcare regulations, including those governing patient data privacy (HIPAA), medical billing, and professional licensing. Compliance with these evolving regulations is critical to avoid penalties and maintain operational integrity.

What Investors Should Do

1. Monitor execution of the strategic pivot.
2. Assess competitive positioning in the wellness market.
3. Analyze the impact of dilution from convertible securities.
4. Evaluate management's ability to execute the new strategy.

Key Dates

• 2024-09-15: Reverse Stock Split Approved — A 1-for-2,000 reverse stock split was approved, which will significantly reduce the number of outstanding common shares prior to listing, impacting per-share metrics and potentially the stock price.

Glossary

Series D Convertible Preferred Stock

A class of stock that pays a fixed dividend and can be converted into a predetermined number of common shares. It ranks higher than common stock in terms of dividend payments and asset distribution in case of liquidation. (This is the primary security being offered in the IPO, with the potential to convert into a significant number of common shares.)

Warrants

A security that gives the holder the right, but not the obligation, to purchase a company's stock at a predetermined price (exercise price) within a specified timeframe. (Offered alongside the preferred stock, these provide an additional avenue for capital infusion and can lead to further dilution of common stock upon exercise.)

Reverse Stock Split

A corporate action where a company reduces the total number of its outstanding shares by consolidating existing shares into fewer, proportionally more valuable shares. (This action is being taken to reduce the share count from 32,958,288 prior to listing, likely to meet exchange listing requirements or improve per-share valuation perception.)

Selling Stockholders

Existing shareholders who are offering their shares for sale in the public offering, distinct from the company selling newly issued shares. (These stockholders may sell up to 720,000 shares, providing liquidity for early investors but not raising new capital for the company.)

Super Voting Preferred Stock

A class of stock that carries significantly more voting rights per share than common stock, often used to maintain control. (The CEO's 4 shares of Series A Super Voting Preferred Stock will be cancelled, eliminating his super-voting control and signaling a shift in corporate governance.)

Year-Over-Year Comparison

This S-1/A filing represents a significant strategic shift for First Choice Healthcare Solutions, Inc., moving away from its historical orthopedic services towards a primary care and wellness clinic model. Key metrics such as revenue, margins, and profitability from the previous business model are likely to be less relevant as the company invests in and builds out its new operations. New risks associated with entering a competitive and regulated wellness market are now prominent, replacing or overshadowing risks associated with the previous business. The capital raise of $12,000,000 is critical for funding this transformation, indicating a substantial investment phase ahead.

Key Financial Figures

• $0.001 — Convertible Preferred Stock, par value $0.001 per share (the "Offered Preferred Stock
• $5 — an assumed initial conversion price of $5 per share and the Warrants will be exer
• $75,000 — le out-of-pocket expenses not exceeding $75,000 payable to RBW Capital Partners LLC act

Filing Documents

• forms-1a.htm (S-1/A) — 3641KB
• ex1-1.htm (EX-1.1) — 89KB
• ex5-1.htm (EX-5.1) — 24KB
• ex23-1.htm (EX-23.1) — 6KB
• ex23-2.htm (EX-23.2) — 6KB
• forms-1_001.jpg (GRAPHIC) — 22KB
• chart_001.jpg (GRAPHIC) — 68KB
• chart_002.jpg (GRAPHIC) — 62KB
• ex23-1_001.jpg (GRAPHIC) — 7KB
• ex23-2_001.jpg (GRAPHIC) — 7KB
• ex1-1_001.jpg (GRAPHIC) — 3KB
• ex1-1_002.jpg (GRAPHIC) — 3KB
• ex5-1_001.jpg (GRAPHIC) — 10KB
• 0001493152-25-026643.txt ( ) — 9677KB
• fchs-20250930.xsd (EX-101.SCH) — 59KB
• fchs-20250930_cal.xml (EX-101.CAL) — 54KB
• fchs-20250930_def.xml (EX-101.DEF) — 240KB
• fchs-20250930_lab.xml (EX-101.LAB) — 389KB
• fchs-20250930_pre.xml (EX-101.PRE) — 297KB
• forms-1a_htm.xml (XML) — 1102KB

Underwriting

Underwriting discounts and commissions (3) $ 0.40 $ 960,000 Proceeds to us (before expenses) $ 4.60 $ 11,040,000 (1) The per share price represents the combined public offering price for one share of Offered Preferred Stock and a Warrant to purchase one share of common stock. The price of a share of the Offered Preferred Stock and accompanying Warrant in this prospectus assumes a combined public offering price of $5 per share and accompanying Warrant and a conversion price and exercise price per share of the Offered Preferred Stock and per Warrant of $5 per share, as the case may be. (2) Assumes no exercise of the over-allotment option to purchase units we have granted to the underwriters as described below. See "Underwriting" on page 73 for a description of total compensation payable to the underwriters. (3) Does not include a reasonable and accountable out-of-pocket expenses not exceeding $75,000 payable to RBW Capital Partners LLC acting through Dawson James Securities, Inc. (the "Representative"), the representative of the underwriters. See "Underwriting" on page 73 for a description of compensation payable to the underwriters. We have granted the underwriters a 45-day option to purchase from us, at the public offering price, less the underwriting discounts, up to 360,000 additional shares of Offered Preferred Stock and/or Warrants to purchase up to 360,000 shares of Warrant Preferred Stock, solely to cover over-allotments, if any. This offering also relates to the additional shares of Offered Preferred Stock and Warrants to purchase shares of Warrant Preferred Stock, issuable upon exercise of the over-allotment option, if any, the common shares issuable upon the exercise of such Offered Preferred Stock and such Warrant Preferred Stock and the shares of common stock issuable upon payment of any dividends accrued on such Offered Preferred Stock and such Warrant Preferred Stock. Unless otherwise noted, the share and per share information in this

DILUTION

DILUTION 32 DESCRIPTION OF CAPITAL STOCK 33 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 36

BUSINESS

BUSINESS 47 MANAGEMENT 62 EXECUTIVE COMPENSATION 64 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 65 SECURITY 65 SHARES ELIGIBLE FOR FUTURE SALE 66 MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS 68

UNDERWRITING

UNDERWRITING 73 DETERMINATION OF OFFERING PRICE 75 INTERESTS OF NAMED EXPERTS AND COUNSEL 75 EXPERTS 75 LEGAL MATTERS 76 WHERE YOU CAN FIND ADDITIONAL INFORMATION 76 INDEX TO FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS The registration statement of which this prospectus forms a part that we filed with the Securities and Exchange Commission (the "SEC") includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus and the related exhibits filed with the SEC, together with the additional information described under the headings "Where You Can Find Additional Information" before making your investment decision. You should rely only on the information provided in this prospectus, in any prospectus supplement or in a related free writing prospectus, or documents to which we otherwise refer you. In addition, this prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. This prospectus includes important information about us, the securities being offered and other information you should know before investing in our securities. You should not assume that the information contained in or incorporated by reference this prospectus is accurate on any date subsequent to the date set forth on the front cover of this prospectus, even though this prospectus is delivered or securities are sold or otherwise disposed of on a later date. It is important for you to read and consider all information contained or incorporated by reference in this prospectus in making your investment decision. All of the summaries in this prospectus are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and

Business

Business Overview First Choice Healthcare Solutions, Inc. ("FCHS," "the Company," "we," "our" or "us") is actively engaged in pivoting the Company's strategy away from our historic orthopedic business model to a strategy of developing a national chain of innovative primary care and wellness clinics focused on providing life improvement services (anti-aging, weight management, and hormone replacement) and pharmacy services, in key high growth markets throughout the U.S. Although we still provide rehabilitative services on a limited basis, such as Physical Therapy, concurrent with the completion of this offering we will terminate all of our remaining legacy orthopedic and Physical Therapy services and focus the company resources on our strategy of building and operating primary care and wellness clinics. Operating Subsidiaries We have operated as First Choice Healthcare Solutions, Inc., a Delaware corporation,

View Full Filing

View this S-1/A filing on SEC EDGAR